• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

组蛋白去乙酰化酶抑制在癌症治疗中的应用：白血病的启示

Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia.

作者信息

Ceccacci Elena, Minucci Saverio

机构信息

Department of Experimental Oncology and Drug Development Program, European Institute of Oncology, Via Adamello 16, 20139 Milan, Italy.

Department of Biosciences, University of Milan, Via Celoria 26, 20133 Milan, Italy.

出版信息

Br J Cancer. 2016 Mar 15;114(6):605-11. doi: 10.1038/bjc.2016.36. Epub 2016 Feb 23.

DOI:10.1038/bjc.2016.36
PMID:26908329
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4800301/
Abstract

Histone deacetylases (HDACs) are a key component of the epigenetic machinery regulating gene expression, and behave as oncogenes in several cancer types, spurring the development of HDAC inhibitors (HDACi) as anticancer drugs. This review discusses new results regarding the role of HDACs in cancer and the effect of HDACi on tumour cells, focusing on haematological malignancies, particularly acute myeloid leukaemia. Histone deacetylases may have opposite roles at different stages of tumour progression and in different tumour cell sub-populations (cancer stem cells), highlighting the importance of investigating these aspects for further improving the clinical use of HDACi in treating cancer.

摘要

组蛋白去乙酰化酶（HDACs）是调控基因表达的表观遗传机制的关键组成部分，并且在多种癌症类型中发挥癌基因的作用，这促使人们研发组蛋白去乙酰化酶抑制剂（HDACi）作为抗癌药物。本综述讨论了关于HDACs在癌症中的作用以及HDACi对肿瘤细胞影响的新结果，重点关注血液系统恶性肿瘤，尤其是急性髓系白血病。组蛋白去乙酰化酶在肿瘤进展的不同阶段以及不同肿瘤细胞亚群（癌症干细胞）中可能具有相反的作用，这凸显了研究这些方面对于进一步改善HDACi在癌症治疗中的临床应用的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6ac/4800301/596062dd66ab/bjc201636f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6ac/4800301/b85360bd9d07/bjc201636f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6ac/4800301/52669c5c443d/bjc201636f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6ac/4800301/596062dd66ab/bjc201636f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6ac/4800301/b85360bd9d07/bjc201636f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6ac/4800301/52669c5c443d/bjc201636f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c6ac/4800301/596062dd66ab/bjc201636f3.jpg

相似文献

1
Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia.组蛋白去乙酰化酶抑制在癌症治疗中的应用：白血病的启示
Br J Cancer. 2016 Mar 15;114(6):605-11. doi: 10.1038/bjc.2016.36. Epub 2016 Feb 23.
2
Paediatric patients with acute leukaemia and KMT2A (MLL) rearrangement show a distinctive expression pattern of histone deacetylases.急性白血病伴 KMT2A（MLL）重排的儿科患者表现出独特的组蛋白去乙酰化酶表达模式。
Br J Haematol. 2018 Aug;182(4):542-553. doi: 10.1111/bjh.15436. Epub 2018 Jul 5.
3
The role of HDACs inhibitors in childhood and adolescence acute leukemias.组蛋白去乙酰化酶抑制剂在儿童及青少年急性白血病中的作用。
J Biomed Biotechnol. 2011;2011:148046. doi: 10.1155/2011/148046. Epub 2011 Jan 13.
4
Histone deacetylases and epigenetic therapies of hematological malignancies.组蛋白去乙酰化酶与血液系统恶性肿瘤的表观遗传学治疗。
Pharmacol Res. 2010 Jul;62(1):18-34. doi: 10.1016/j.phrs.2010.02.010. Epub 2010 Feb 26.
5
Histone deacetylase inhibitors in the treatment of hematological malignancies.组蛋白去乙酰化酶抑制剂在血液系统恶性肿瘤治疗中的应用。
Mini Rev Med Chem. 2011 Jun;11(6):519-27. doi: 10.2174/138955711795843347.
6
Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53.通过组蛋白去乙酰化酶抑制在肿瘤细胞中靶向自噬：p53 的作用。
Int J Mol Sci. 2018 Dec 8;19(12):3952. doi: 10.3390/ijms19123952.
7
Inhibition of histone deacetylases in melanoma-a perspective from bench to bedside.黑色素瘤中组蛋白去乙酰化酶的抑制——从 bench 到 bedside 的视角
Exp Dermatol. 2016 Nov;25(11):831-838. doi: 10.1111/exd.13089.
8
Analysis of class I and II histone deacetylase gene expression in human leukemia.人类白血病中I类和II类组蛋白去乙酰化酶基因表达分析
Leuk Lymphoma. 2015;56(12):3426-33. doi: 10.3109/10428194.2015.1034705. Epub 2015 May 26.
9
Is dual inhibition of metalloenzymes HDAC-8 and MMP-2 a potential pharmacological target to combat hematological malignancies?金属酶HDAC - 8和MMP - 2的双重抑制作用是对抗血液系统恶性肿瘤的潜在药理学靶点吗？
Pharmacol Res. 2017 Aug;122:8-19. doi: 10.1016/j.phrs.2017.05.002. Epub 2017 May 10.
10
HDACs and HDAC Inhibitors in Cancer Development and Therapy.组蛋白去乙酰化酶及组蛋白去乙酰化酶抑制剂在癌症发生与治疗中的作用
Cold Spring Harb Perspect Med. 2016 Oct 3;6(10):a026831. doi: 10.1101/cshperspect.a026831.

引用本文的文献

1
Potential risks of histone deacetylase inhibitors in cancer therapeutics and feasible combination therapeutic strategies.组蛋白去乙酰化酶抑制剂在癌症治疗中的潜在风险及可行的联合治疗策略。
World J Clin Oncol. 2025 Aug 24;16(8):108768. doi: 10.5306/wjco.v16.i8.108768.
2
DNA Methylation in Ph-Negative Myeloproliferative Neoplasms: Prognostic Role and Therapeutic Implications.阴性骨髓增殖性肿瘤中的DNA甲基化：预后作用及治疗意义
Curr Issues Mol Biol. 2025 Mar 26;47(4):227. doi: 10.3390/cimb47040227.
3
LncRNA-Histone Modification Crosstalk: Orchestrating Cancer Pathobiology.

本文引用的文献

1
Clinical Toxicities of Histone Deacetylase Inhibitors.组蛋白去乙酰化酶抑制剂的临床毒性
Pharmaceuticals (Basel). 2010 Aug 26;3(9):2751-2767. doi: 10.3390/ph3092751.
2
Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies.小鼠淋巴和髓系恶性肿瘤中组蛋白去乙酰化酶依赖性的功能基因剖析
Blood. 2015 Nov 19;126(21):2392-403. doi: 10.1182/blood-2015-03-632984. Epub 2015 Oct 7.
3
Novel types and sites of histone modifications emerge as players in the transcriptional regulation contest.新型组蛋白修饰类型及位点成为转录调控竞争中的参与者。
长链非编码RNA与组蛋白修饰的相互作用：调控癌症病理生物学
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jul 11. doi: 10.1007/s00210-025-04402-6.
4
New potent N-hydroxycinnamamide-based histone deacetylase inhibitors suppress proliferation and trigger apoptosis in THP-1 leukaemia cells.新型强效N-羟基肉桂酰胺类组蛋白去乙酰化酶抑制剂可抑制THP-1白血病细胞增殖并引发凋亡。
Arch Pharm (Weinheim). 2025 Apr;358(4):e2400889. doi: 10.1002/ardp.202400889.
5
Computationally Guided Design, Synthesis, and Evaluation of Novel Non-Hydroxamic Histone Deacetylase Inhibitors, Based on -Trifluoroacetamide as a Zinc-Binding Group, Against Breast Cancer.基于三氟乙酰胺作为锌结合基团的新型非异羟肟酸类组蛋白去乙酰化酶抑制剂的计算辅助设计、合成及对乳腺癌的评估
Pharmaceuticals (Basel). 2025 Feb 28;18(3):351. doi: 10.3390/ph18030351.
6
The histone modifier KAT2A presents a selective target in a subset of well-differentiated microsatellite-stable colorectal cancers.组蛋白修饰因子KAT2A是一部分高分化微卫星稳定型结直肠癌的选择性靶点。
Cell Death Differ. 2025 Mar 27. doi: 10.1038/s41418-025-01479-7.
7
HDAC7 drives glioblastoma to a mesenchymal-like state via LGALS3-mediated crosstalk between cancer cells and macrophages.组蛋白去乙酰化酶7通过半乳糖凝集素3介导的癌细胞与巨噬细胞之间的串扰，将胶质母细胞瘤驱动至间充质样状态。
Theranostics. 2024 Oct 21;14(18):7072-7087. doi: 10.7150/thno.100939. eCollection 2024.
8
Study of TRAIL and SAHA Co-Treatment on Leukemia K562 Cell Line.TRAIL与SAHA联合治疗白血病K562细胞系的研究
Cell Biochem Biophys. 2025 Mar;83(1):1087-1096. doi: 10.1007/s12013-024-01543-y. Epub 2024 Oct 11.
9
Selective inhibition of HDAC class IIA as therapeutic intervention for KMT2A-rearranged acute lymphoblastic leukemia.选择性抑制 HDAC ⅡA 类作为治疗 KMT2A 重排急性淋巴细胞白血病的方法。
Commun Biol. 2024 Oct 4;7(1):1257. doi: 10.1038/s42003-024-06916-w.
10
Advances in the Histone Acetylation Modification in the Oral Squamous Cell Carcinoma.口腔鳞状细胞癌中组蛋白乙酰化修饰的研究进展
J Oncol. 2023 Feb 9;2023:4616682. doi: 10.1155/2023/4616682. eCollection 2023.
FEBS J. 2015 May;282(9):1658-74. doi: 10.1111/febs.13047. Epub 2014 Oct 7.
4
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.组蛋白去乙酰化酶及其抑制剂在癌症、神经疾病和免疫紊乱中的作用。
Nat Rev Drug Discov. 2014 Sep;13(9):673-91. doi: 10.1038/nrd4360. Epub 2014 Aug 18.
5
Evolution of the cancer stem cell model.癌症干细胞模型的演变。
Cell Stem Cell. 2014 Mar 6;14(3):275-91. doi: 10.1016/j.stem.2014.02.006.
6
New Insights into the Connection Between Histone Deacetylases, Cell Metabolism, and Cancer.组蛋白去乙酰化酶、细胞代谢与癌症之间联系的新见解
Antioxid Redox Signal. 2015 Jul 1;23(1):30-50. doi: 10.1089/ars.2014.5854. Epub 2014 Mar 6.
7
Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011 - 2013).用于治疗癌症和非癌症疾病的组蛋白去乙酰化酶小分子抑制剂：专利综述（2011 - 2013年）
Expert Opin Ther Pat. 2014 Apr;24(4):401-15. doi: 10.1517/13543776.2014.877446. Epub 2014 Jan 8.
8
New and emerging HDAC inhibitors for cancer treatment.新型和新兴的 HDAC 抑制剂在癌症治疗中的应用。
J Clin Invest. 2014 Jan;124(1):30-9. doi: 10.1172/JCI69738. Epub 2014 Jan 2.
9
Divergent roles of HDAC1 and HDAC2 in the regulation of epidermal development and tumorigenesis.HDAC1 和 HDAC2 在表皮发育和肿瘤发生中的调控作用存在差异。
EMBO J. 2013 Dec 11;32(24):3176-91. doi: 10.1038/emboj.2013.243. Epub 2013 Nov 15.
10
Widespread and enzyme-independent Nε-acetylation and Nε-succinylation of proteins in the chemical conditions of the mitochondrial matrix.在基质化学条件下广泛存在且酶非依赖性的蛋白质 Nε-乙酰化和 Nε-琥珀酰化。
J Biol Chem. 2013 Oct 4;288(40):29036-45. doi: 10.1074/jbc.M113.486753. Epub 2013 Aug 13.